Watch this video, where Prof. Charlotte Teunissen talks about the purpose of biomarkers in providing a timely diagnosis of #AlzheimersDisease . #CTAD23

Dr. Alberto Lleó shares his views on the advances in the field of #AlzheimersDisease and how it has evolved over the last decades. Watch the video now. #CTAD23

aw the snowflakes are all starting to block me because i keep pointing out the obvious fact that $SAVA failed their phase 2 endpoints based on their own data and #ctad23 talk

Nice! #CTAD23

It has been a pleasure to join global experts at #CTAD23 to discuss the future of #AlzheimersDisease . What were your personal highlights from the past couple of days?

Y'all should go see Dr. Monica Rivera Mindt at CTAD!🙌 #CTAD23 #Alzheimers #AD #equity

Really cool work from Bruna Bellaver at #CTAD23 on astrocyte-positive #enrichment strategies for clinical trials on Alzheimer's disease.

Join Lilly Medical at #CTAD23 on Thursday, October 26 for our symposium, ‘What can we LEARN from the A4 study: Associations between longitudinal, cognitive, functional, biomarker, and imaging outcomes.’

Learn more: e.lilly/46KGZYo

There’s so much to learn at #CTAD23 !

Check out this Breakfast Briefing on today's abstracts, presented by Dr. Anna D. Burke.

To earn credit, reflect on the briefing here: earnc.me/kkpsuX

For more info: cmeo.me/CTADBB3

#AlzheimersDisease #MedEd #FOAMed …

Our blinded data presented at #CTAD23 suggest that NE3107 is biologically active and may have an impact across endpoints. Topline data from the Phase 3 trial in mild to moderate #AlzheimersDisease are anticipated in late Nov/early Dec.

Learn more: feeds.issuerdirect.com/news-release.h…

$BIVI

A quick search of the upcoming #CTAD23 program renders multiple poster presentations that reference p-tau181 for: trial screening, enrichment, cognition staging, etc.. It's very reassuring that $SAVA is employing p-tau181 in its ongoing Phase 3 #simufilam clinical trials.

With #CTAD23 happening, it is an exciting week for the AD field. To contribute to the discussion, we (I, Joe Winer, and Mike Greicius) wanted to highlight three observations regarding recent anti-amyloid clinical trials:

arxiv.org/abs/2310.15456

a step closer to improving early AD diagnosis.
#Alzheimers #CTAD23

U.S. FDA The City University of New York Research Integrity the colossal failure of the $SAVA p2 CMS withdrawal results presented at #ctad23 just solidifies the need for an immediate futility analysis. a real drug company wouldve dropped simufilam on these data with zero hesitation

Let's go $SAVA sisters! Our fav company just PR'd more evidence that their drug is inert!
#CTAD23

#CTAD23 Attendees - Thank you to everyone who joined us in Boston for the CTAD23 congress.

Learn more: e.lilly/3Qk5ztv

#Neuroscience

One of my favorite scientists telling great science stories, thank you, ⁦@relajoie⁩ for making even complicated research accessible!! #CTAD23

We are excited to be at #CTAD23 in Boston today, discussing the latest data and perspectives that are driving innovation for people affected by #Alzheimers disease. Hear from our Chief Medical Officer, Hideki Garren, on the future of Alzheimer’s disease treatments.

On today’s #BiotechHangout Daphne Zohar josh schimmer Brad Loncar Bruce Booth Dawn Bell and Paul Matteis cover #CTAD23 , #WorldSleepCongress , Bipartisan biopharma initiatives being advanced in Congress, OrbiMed $4.3B fund & are big VC rounds back, $ROIV/$RHHBY Telavant acquisition,…

Slide Deck from the #CTAD23 presentation. $sava

cassavasciences.com/static-files/2…